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Abstract 
Fluorogenic 6-acylamino-4-methylumbelliferyl-/3-D-glucosides were found to be poor substrates for the three known human /3-gluco- 
sidases, i.e., lysosomal and non-lysosomal g ucocerebrosidases and cytosolic broad-specificity /3-glucosidase. However, homogenates of 
human tissues and human cell types showed significant enzymatic hydrolysis of 6-ethanoylamino-4-methylumbelliferyl-/3-D-glucoside 
(EMGlc) due to the activity of a hitherto undescribed /3-glucosidase, called here EMGlc-ase. It was shown that the isozyme is hardly 
active towards 4-methylumbelliferyl-/3-D-glucoside r glucosylceramide. EMGlc-ase exhibits maximal activity at pH 4.5 and 5.0 in the 
absence and presence of sodium taurocholate r spectively. It is a soluble lysosomal enzyme with a discrete isoelectric point of about 5.0. 
EMGlc-ase is not inhibited by conduritol B-epoxide, is activated by sodium taurocholate and binds strongly to Concanavalin A. This 
enzyme is not deficient in relation to Gaucher disease. 
Keywords: Human fl-glucosidases; Gaucher disease; Fluorogenic substrates 
1. Introduction 
fl-Glucosidic linkages are rare in mammalian cells. The 
only known endogenous substrate for/3-glucosidases is the 
glycosphingolipid glucosylceramide (glucocerebroside) 
Abbreviations: MGIc, 4-methylumbelliferyl-fl-D-glucoside; EMGIc, 
6-ethanoylamino-4-methylumbelliferyl-fl-D-glucoside; BMGlc, 6- 
butanoylamino-4-methylumbelliferyl-/3-D-glucoside; OMGIc, 6-octanoy- 
lamino-4-methylumbelliferyl-/3-D-glucoside; HMGlc, 6-hexadecanoy- 
lamino-4-methylumbelliferyl-fl-D-glucoside; MGIcNAc, 4-methylumbel- 
liferyl-2-acetamido-2-deoxy-fl-o-glucoside; TCh, sodium taurocholate; 
CBE, conduritol B epoxide; SAP-2, sphingolipid activator protein 2 
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which is assumed to be catabolized specifically in lyso- 
somes. Nevertheless, in human tissues and cell types vari- 
ous fl-glucosidase activities are observed. The best known 
enzyme is lysosomal glucocerebrosidase (EC 3.2.1.45); 
this enzyme is present in all cell types. It is a weakly 
membrane-associated glycoprotein of 497 amino acids 
containing 4 N-linked glycans. The glucocerebrosidase 
gene is located on chromosome 1 locus q21. A deficiency 
in lysosomal glucocerebrosidase forms the basis of an 
inherited lysosomal storage disorder in man, called Gaucher 
disease. The manifestation of Gaucher disease is clinically 
heterogeneous. Three phenotypes of the disease are distin- 
guished on the basis of clinical severity, age of onset and 
neuronal involvement: ype 1 (adult form), type 2 (infantile 
form) and type 3 (juvenile form) (for recent reviews, see 
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Refs. [1,2]). The lysosomal glucocerebrosidase i  active 
not only towards the natural lipid substrate glucosylce- 
ramide but also to a number of artificial /3-D-glucosidic 
and /3-D-xylosidic substrates, uch as fluorogenic 4-meth- 
ylumbelliferyl derivatives [3]. The enzyme has an acid pH 
optimum (4.5-5.0) [4] and is very heterogeneous in iso- 
electric point (pI values ranging from 3.5 to 7.0) [5]. It is 
irreversibly inhibited by conduritol B-epoxide (CBE) [6], is 
activated by sodium taurocholate (TCh) [7] and, also, by 
phosphatidylserine i  combination with the sphingolipid 
activator protein 2 (SAP-2) [8]. 
The existence of a second, non-lysosomal tightly mem- 
brane-bound glucocerebrosidase hasbeen reported in many 
tissues and cell types [9]. This enzyme seems to be identi- 
cal to the enzyme previously described as membraneous 
non-specific /3-glucosidase [10-13]. Like the lysosomal 
enzyme, non-lysosomal g ucocerebrosidase i  able to hy- 
drolyze glucosylceramide and 4-methylumbelliferyl-/3-D- 
glucoside, but it differs from lysosomal glucocerebrosidase 
in several properties. In particular, it is strongly mem- 
brane-bound, is not located in lysosomes, has a more 
neutral pH optimum, is markedly inhibited by detergents, 
is not inhibited by CBE and is not deficient in Gaucher 
disease [9]. The physiological role of the enzyme is as yet 
unknown. 
In most tissues, especially in liver, kidney and spleen, 
there occurs a cytosolic broad-specificity /3-glucosidase 
(EC 3.2.1.21) with near neutral pH optimum [14-18]. This 
enzyme does not hydrolyze glucosylceramide but displays 
a broad specificity towards /3-o-glucosidic, /3-D-galacto- 
sidic, /3-o-fucosidic, /3-D-xylosidic and t~-L-arabinosidic 
derivatives of 4-methylumbelliferone and p-nitrophenol 
[14,15]. The physiological substrate for the cytosolic 
broad-specificity /3-glucosidase is yet unknown. This en- 
zyme is not a glycoprotein; it is located in the cytosol and 
shows a discrete isoelectric point of 4.6 [15]. It is not 
inhibited by CBE, is inhibited by TCh and phos- 
phatidylserine [15,17] and is not deficient in Gaucher 
disease [19]. 
4-Methylumbelliferyl-/3-~glucoside i  a fluorogenic 
substrate generally used for detection of /3-glucosidase 
activities. We have investigated the ability of various 
known /3-glucosidase to hydrolyze a series of newly syn- 
thesized fluorogenic 6-acylamino-4-methylumbelliferyl-/3- 
D-glucosides with variable acyl-chain length [20]. Based on 
their structural similarity to glucosylceramide, weexpected 
these compounds to be better/or more specific substrates 
for glucocerebrosidases as compared to 4-methylumbel- 
liferyl-/3-D-glucoside. However, this actually was not the 
case. Nevertheless, the use of the novel substrates led us to 
the discovery of a hitherto undescribed /3-glucosidase of
which a number of characteristics are described. 
2. Materials and methods 
2.1. Materials 
Sodium taurocholate (TCh) was purchased from Fluka 
(Buchs, Switzerland), 4-methylumbelliferyl-/3-I>glucoside, 
Concanavalin A Sepharose-4B, castanospermine and de- 
oxynojirimycin were from Sigma (St. Louis, MO, USA), 
4-methylumbelliferyl-2-acetamido-2-deoxy-/3-D-glucoside 
was from Calbiochem (San Diego, CA, USA), conduritot 
B epoxide (CBE) was obtained from Biomol Research 
Laboratories (Philadelphia, PA, USA) and Percoll from 
Pharmacia (Uppsala, Sweden). All other chemicals were of 
the purest grade available. 
6-Acylamino-4-methylumbelliferyl-/3-D-glucosides were 
synthesized asdescribed previously [20]. The 6-acylamino- 
4-methylumbelliferone derivatives were obtained by acyla- 
tion of 6-amino-4-methylumbelliferone [21] with the acyl 
chlorides of the corresponding carbonic acids and glycosy- 
lated by the Koenigs-Knorr method. The structure of the 
newly synthesized compounds was confirmed by elemental 
analysis and 1H-NMR spectroscopy. The configuration of 
the 1,2-trans-glucoside bond was confirmed by the pres- 
ence in the 1H-NMR spectrum of a doublet at delta 4.9-5.0 
(Ji,2 7.9-8.0 Hz). The fluorescence of aglycons was simi- 
lar to that described earlier for 4-methylumbelliferone. 
2.2. Tissue and cells 
Spleen samples were obtained as surgical specimens 
during therapeutic splenectomy or by autopsy. Liver and 
kidney were from autopsy material. The phenotype of the 
Gaucher patients was established by clinical investigation. 
Type 1 Gaucher fibroblasts were obtained from the Insti- 
tute of Medical Genetics, Russian Academy of Sciences, 
and type 2 Gaucher fibroblasts were kindly provided by 
Dr. Y. Suzuki from Tokyo Metropolitan I stitute of Medi- 
cal Sciences. 
Human blood leukocytes were isolated by the dextran 
method as described in [22]. 
Tissues were homogenized in Potter homogenizer in 5 
vol. (w/v) of 10 mM potassium phosphate/100 mM NaC1 
(pH 6.0), containing 0.5% (w/v) Triton X-100. All proce- 
dures were performed at 4°C. 
2.3. Purification of ~-glucosidases 
Lysosomal glucocerebrosidase was purified from hu- 
man spleen by immunoaffinity chromatography as de- 
scribed in Ref. [23]. The cytosolic broad-specificity /3-glu- 
cosidase was isolated from type 1 Gaucher disease spleen 
as described in Ref. [15]. 
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The membrane-bound non-lysosomal glucocerebrosi- 
dase was partially purified as follows. Spleen from type 1 
Gaucher disease patient was homogenized in 4 vols. of 50 
mM sodium citrate buffer (pH 6.0) using an Ultraturrax 
homogenizer. The homogenate was centrifuged for 1 h at 
80 000 × g. The supernatant was discarded and the pellet 
redissolved in the same buffer by sonication. The suspen- 
sion was again subjected to ultracentrifugation a d the 
resulting pellet resuspended in sodium citrate buffer. In 
order to eliminate the contribution of residual lysosomal 
glucocerebrosidase to the acid /3-glucosidase activity, the 
suspension was incubated for 30 min with 5 mM CBE. 
2.4. Enzyme assays 
To measure/3-glucosidase ctivities, the following fluo- 
rogenic substrates were used: 4-methylumbelliferyl-/3-D- 
glucoside (MGIc), 6-ethanoyl-, 6-butanoyl-, 6-octanoyl- 
and 6-hexadecanoylamino-4-methylumbelliferyl-/3-D-glu- 
cosides (EMGlc, BMGlc, OMGIc and HMGIc, respec- 
tively). If not indicated otherwise, the reaction mixture 
(final volume 0.2 ml) contained 2.2 mM MGIc or 1 mM 
EMGIc, BMGIc, OMGIc or HMGlc, 50/100 mM 
citrate/phosphate (pH 5.0), 0.6% (w/v)  TCh and the 
enzyme preparation. (0.05-0.2 mg of protein). After 15- 
180 min at 37°C, the reaction was terminated by addition 
of 2 ml of 0.4 M glycine-NaOH (pH 10.5) with MGIc as 
substrate. When EMGlc, BMGlc, OMGIc or HMGlc were 
used as substrates, the reaction terminating solution also 
contained 66% (v /v)  ethanol. The fluorescence of the 
liberated 4-methylumbelliferone was measured in Shi- 
madzu RF-5000 spectrofluorometer using an excitation 
wavelength of 365 nm and emission wavelength of 450 nm 
and the fluorescence of 6-acylamino-4-methylumbel- 
liferones, using an excitation wavelength of 385 nm and 
emission wavelength of 450 nm. 
/3-Hexosaminidase was measured with 4-methylumbel- 
liferyl-2-acetamido-2-deoxy-fl-D-glucoside (MGlcNAc) at 
a final concentration of 1.6 mM in 0.1 M acetate buffer 
(pH 5.0). The reaction was stopped by adding 2.0 ml of 
0.4 M glycine-NaOH (pH 10.5) and the 4-methylumbel- 
liferone formed was determined fluorometrically. 
2.5. Subcellular f actionation 
Rat liver, previously perfused with cold 250 mM su- 
crose, 5 mM Tris/HCl (pH 7.0) and 1 mM EDTA, was 
homogenized in a Potter homogenizer in 6 vol. of the same 
solution for 1 min at 0°C. Homogenate was centrifuged for 
5 min at 700 × g and the resulting postnuclear supernatant 
was layered on Percoll material with a starting density of 
1.09 g/ml.  Continuous gradient was generated in situ by 
centrifugation at 30000 × g for 60 min at 4°C using 
Beckman 50 Ti fixed angle rotor. Fractions of 0.3 ml each 
were collected from gradient. 
2.6. Isoelectric focusing 
Preparative flat-bed isoelectric focusing in Ultrodex 
containing 1% (v/v)  Triton X-100 was performed 
overnight at 500 V using a LKB 2117 Multiphor apparatus 
as described by the manufacturer. The gel was fractionated 
and the fractions of gel material were extracted with 
distilled water. 
3. Results 
3.1. Comparison of the rates of hydrolysis of various 
fluorogenic substrates by purified fl-glucosidases from 
human spleen 
The specific activity of known fl-glucosidases (lyso- 
somal glucocerebrosidase, non-lysosomal glucocerebrosi- 
dase and cytosolic broad-specificity /3-glucosidase) from 
human spleen towards MGlc, EMGlc, BMGlc, OMGlc and 
Table 1 
Specific activity of purified fl-glucosidases towards artificial substrates 
Substrate Spec. act. (nmol/h per mg protein) 
Lysosomal g ucocerebrosidase Soluble broad-specificity/3-glucosidase a Non-lysosomal glucocerebrosidase b 
MGlc 2 300 000 77.3 4.9 
EMGlc 48 300 1.6 0.25 
BMGIc 22 800 0.8 0.17 
OMGlc 13 200 0.2 0.10 
HMGlc 2 200 0.05 0 
MGlc/EMGIc c 47.6 48.0 19.6 
a Activity was measured in the absence ofTCh at pH 6.0. 
b Activity was measured in the absence ofTCh at pH 5.5. 
c The ratio of specific activities. 
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Table 2 
/3-Glucosidase activities in human tissues and cell extracts 
Source Spec. act. (nmol/h per mg protein) 
MGlc EMGlc BMGIc OMGlc HMGIc MGlc/EMGlc a 
Liver 47 8.0 3.8 1.7 0.06 5.9 
Kidney 46 7.3 3.5 1.5 0.06 6.3 
Spleen 10.5 1.9 0.5 0.3 0.01 5.5 
Fibroblasts 130 12.3 4.6 2.5 0.7 10.6 
Leukocytes 7.0 3.9 1.6 0.6 0.2 1.8 
a The ratio of specific activities. 
Table 3 
/3-Glucosidase activities in extracts of fibroblasts and spleens from control subjects and Gaucher disease patients 
Source Spec. act. (nmol/h per mg protein) 
MGlc EMGIc BMGIc OMGIc HMGIc 
Fibroblasts 
Control (5) mean 124.6 12.0 4.3 2.1 0.6 
Range 94.5-143.8 9.3-14.1 3.4-4.8 1.3-2.5 0.4-0.7 
Type 1 patient 10.5 11.9 4.3 1.9 0.5 
Type 2 patient 5.6 9.1 3.4 1.4 0.6 
Spleen 
Control (3) mean 10.5 1.8 0.6 0.4 0.02 
Range 9.8-11.3 1.4-2.2 0.4-0.7 0.3-0.6 0.01-0.03 
Type 1 patient 2.0 1.5 0.8 0.6 0.03 
Type 2 patient 1.3 1.7 0.7 0.4 0.02 
HMGlc was investigated. Table 1 shows that lysosomal 
glucocerebrosidase, cytosolic broad-specificity /3-gluco- 
sidase and, to a lesser extent, non-lysosomal glucocere- 
brosidase are able to hydrolyze MGlc much better than 
6-acylamino-4-methylumbelliferyl-/3-D-glucosides. The 
rate of hydrolysis of the best substrate from this series, 
EMGIc, by lysosomal glucocerebrosidase nd by cytosolic 
broad-specificity /3-glucosidase was approximately 50 
times, and by non-lysosomal g ucocerebrosidase, 20 times 
lower than that of MGlc. Moreover it was noted that 
6-acylamino-4-methylumbelliferyl-fl-D-glucosides wer  
very poor inhibitors of MGlc hydrolysis by various /3-glu- 
cosidases (not shown). It has to be concluded that the 
novel substrates are not an attractive alternative to MGlc 
for the measurement of activity of the above mentioned 
enzymes. 
3.2. Comparison of the rates of hydrolysis of various 
fluorogenic substrates by homogenates of human tissues 
and cell types 
The hydrolysis of different fluorogenic substrates by 
homogenates of various human tissues and cell types was 
investigated. As seen in Table 2, most materials exhibit a 
significant hydrolytic activity towards 6-acylamino-4- 
methylumbelliferyl-/3-D-glucosides. In fact, the observed 
hydrolysis rates of these substrates by homogenates are 
higher than would be expected based on activities of the 
three known /3-glucosidases (compare Tables 1 and 2). In 
this case the ratios of MGIc/EMGlc activities ranged from 
2 to 11 depending on tissue or cell types. It should be 
noted, that the activity towards 6-acylamino-4-methyl- 
umbelliferyl-/3-D-glucosides in all tissues and cell types 
investigated was not reduced in the presence of CBE (not 
shown). 
These findings suggest the presence of another enzyme 
with /3-glucosidase activity, further eferred to as EMGlc- 
ase. 
Table 4 
Distribution of MGIc and EMGIc activities between particulate and 
soluble fraction of human kidney 
Fraction Recovery of/3-glucosidase activities 
MGlc act. (%) EMGlc act. (%) 
Soluble 39 92 
Particulate 58 7 
Human kidney was homogenized in 4 vol. (w/v)  50 mM potassium 
phosphate (pH 6.0), centrifuged for 1 h at 80000X g and supernatant 
collected. Membrane pellet was resuspended in the same buffer by 
sonication. Activities were measured as described in Section 2. 
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3.3. The hydrolysis of various fluorogenic substrates by 
enzyme preparations from Gaucher disease patients 
The /3-glucosidase activities towards MGlc and 6- 
acylamino-4-methylumbelliferyl-fl-D-glucosides were de- 
termined in homogenates of skin fibroblasts and spleens 
from normal subjects and patients with different pheno- 
types of Gaucher disease. Table 3 shows that in all ho- 
mogenates from Gaucher disease patients the activity to- 
wards MGlc was severely reduced, being always less than 
20% of control values. The rate of hydrolysis of EMGlc, 
as well as other 6-acylamino-4-methylumbelliferyl-/3-D- 
glucosides, by homogenates from Gaucher disease patients 
was not significantly reduced irrespective of clinical phe- 
notype of the disorder. 
3.4. Comparison of distribution of MGlc-ase and EMGlc- 
ase activities after ultracentrifugation 
Table 4 shows the distribution of MGlc-ase and 
EMGlc-ase activities in the 80 000 × g supernatant and in 
particulate fraction, derived from human kidney ho- 
mogenate. The results indicate that the activity towards 
EMGlc is predominantly recovered in the soluble protein 
fraction, whereas about 60% of MGlc-ase activity is pre- 
sent in particulate fraction. 
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Fig. 2. Isoelectric focusing of fl-glucosidases from human kidney. Activi- 
ties were measured with MGIc (m) and with EMGIc (D)  in the presence 
of 0.6% (w/v)  TCh. 
3.5. Gel filtration 
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Fig. 1. Elution profiles of the fl-glucosidase activities in an extract of 
human kidney on Sephadex G-100. Bed dimensions: 1×40 cm, eluent: 
0.1 M citrate buffer, pH 6.0. Activities of fl-glucosidases were measured 
as follows: lysosomal glucocerebrosidase (• ) as CBE-sensitive hydroly- 
sis of MGlc in the presence of 0.6% (w/v)  TCh; soluble broad-specificity 
fl-glucosidase ([])  as CBE-insensitive hydrolysis of MGlc without fur- 
ther additions; EMGlc-ase (O)  as CBE-insensitive hydrolysis of EMGlc 
in the presence of 0.6% (w/v)  TCh. 
A soluble protein fraction prepared from human kidney 
was subjected to Sephadex G-100 gel filtration. Fig. 1 
shows that EMGlc-ase activity was separated from soluble 
broad-specificity fl-glucosidase activity but not from lyso- 
somal glucocerebrosidase ctivity (both enzymes howing 
an apparent molecular mass of about 120-140 kDa). 
3.6. Isoelectric focusing 
A soluble protein fraction prepared from human kidney 
was subjected to isoelectric focusing as described in Sec- 
tion 2. After fractionation of the gel, the fl-glucosidase 
activities in the individual fractions were determined with 
MGlc and EMGIc as substrates (Fig. 2). EMGlc-ase activ- 
ity shows a discrete pl of about 5.0, whereas the MGlc-ase 
activity profile, reflecting the distribution of soluble 
broad-specificity fl-glucosidase and lysosomal glucocere- 
brosidase, is very heterogeneous in isoelectric point (with 
pl values ranging from 4.0 to 7.6). 
3.7. Concanavalin A-Sepharose chromatography 
EMGlc-ase from human kidney, was separated from 
glucocerebrosidase and soluble broad-specificity /3-gluco- 
sidase by chromatography on Con A-Sepharose (Fig. 3). 
Tissue was homogenized in 4 vols. of 50 mM acetate 
76 M. Mikhaylova et al. / Biochimica et Biophysica Acta 1317 (1996) 71-79 
300 
O 250 
~d 
200 
"~ 150 
loo  
0 
e 50 
N 
0 
0 
i .  
v -  
1 2 
1 
5 10 15 20 25 30 
F rac t ion  number  
Fig. 3. Chromatography /3-glucosidases from human kidney on Con 
A-Sepharose 4B. Activities of fl-glucosidases were measured with MGlc 
without (• )  or with (•) 0.6% (w/v)  TCh and with EMGIc in the 
presence of 0,6% (w/v)  TCh (O). At the points indicated by arrows 1 
and 2 elution was started with buffer A, containing 0.1 M and 0.4 M 
ct-D-methylmannoside, respectively. 
buffer (pH 5.3), containing 0.9% NaC1 (buffer A) and the 
homogenate was subjected to ultracentrifugation. The solu- 
ble fraction was applied to a Con A-Sepharose column. 
The EMGlc-ase activity was completely bound. Next, the 
column was washed with buffer A until no /3-glucosidase 
activity was detected in the eluant. Bound glucocerebrosi- 
dase activity was then eluted with this buffer, containing 
0.1 M a-D-methylmannoside (fractions 13-18). EMGlc-ase 
activity was eluted with the same buffer containing 0.4 M 
a-D-methylmannoside. Fractions with EMGlc-ase activity 
were pooled (fractions 20-25), incubated for 30 min with 
5 mM CBE to eliminate the residual glucocerebrosidase 
activity and used in subsequent experiments to study 
EMGlc-ase properties. Control experiments show that c~- 
D-methylmannoside in any concentrations used has no 
effect on EMGlc-ase activity. 
The possibility cannot be excluded that a small amount 
(1-2%) of an unidentified impurity in the EMGlc prepara- 
tion is a substrate for a hypothetical g ycosidase X differ- 
ing from EMGlc-ase. Then the activity of fractions 20-25 
would be associated with glycosidase X rather than with 
our enzyme. If this is the case then the amount of produced 
aglycon would not exceed 1-2% of the substrate added 
irrespective of incubation time. To exclude this possibility 
additional experiments were carded out and it was found 
that fractions 20-25 was able to hydrolyze up to 50% of 
the substrate, indicating that just EMGIc was hydrolyzed 
by this enzyme preparation. 
3.8. pH optimum and effect of detergents 
The effect of pH on EMGlc-ase activity (fractions 
20-25) was investigated. As seen in Fig. 4, the enzyme 
has a pH optimum at pH 4.5 when activity was determined 
in the absence of detergents. In the presence of 0.6% 
(w/v)  TCh, the enzyme activity maximum was shifted to 
pH 5.0. 
The effect of TCh and Triton X-100 on EMGlc-ase 
activity was examined at pH 5.0. Fig. 5 shows that 
EMGlc-ase activity is strongly stimulated by TCh. Maxi- 
mal stimulation, representing a threefold increase in activ- 
ity, occurred at detergent concentrations 0.6-0.7% (w/v). 
Triton X-100 did not produce appreciable stimulation of 
EMGlc-ase activity at any of the concentrations studied. 
3.9. Substrate specificity and inhibitor sensitivity 
The substrate specificity of EMGlc-ase (fractions 20- 
25) is shown in Table 5. The activity of the enzyme 
towards EMGlc was about 20-fold higher as compared to 
MGlc. With elongation of the fatty acid' s acyl chain length 
from 2 to 16 carbon atoms the rate of hydrolysis of 
6-acylamino-4-methylumbelliferyl-fl-D-glucosides wa  sig-
nificantly decreased. The enzyme is not active towards 
glucosylceramide (data not shown). 
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Fig. 4. pH-Profile of EMGlc-ase activity. EMGlc-ase activity was mea- 
sured as described in Section 2 without further additions ([])  and with 
0.6% (w/v)  TCh (• ) .  
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Fig. 5. Effect of TCh (• )  and Triton X-100 (rn) at varying concentra- 
tions on EMGlc-ase activity. 
Table 6 
Effect of various inhibitors on EMGlc-ase from human kidney 
Addition Final concn. EMGlc-ase activity 
(mM) (% of control) 
CBE 5 99.8 
methyl -D-Xyloside 50 97.9 
methyl-D-Glucoside 50 108.5 
D-(l,5)-Gluconolactone 50 114.9 
Castanospermine 5 56.7 
Deoxynojirimycin 5 66.0 
glucocerebrosidase while the non-lysosomal glucocere- 
brosidase is localized in compartments with a considerably 
lower density. 
4. Discussion 
The effect of various inhibitors of /3-glucosidases on 
EMGlc-ase was investigated. As shown in Table 6, cas- 
tanospermine and deoxynojirimycin, which are known to 
be potent competitive inhibitors of lysosomal glucocere- 
brosidase [24,25], are much less effective with EMGlc-ase. 
methyl-D-Glucoside, methyl-D-xyloside and o-(1,5)-gluco- 
nolactone have no effect on EMGlc-ase activity. Besides, 
this activity is not inhibited by CBE. 
3.10. Subcellular localization of EMGlc-ase 
The subcellular localization of EMGlc-ase and other 
fl-glucosidases was determined by Percoll density gradient 
fractionation. For practical reasons, rat liver was used. Fig. 
6 shows that distribution of EMGlc-ase activity is similar 
to the distribution of lysosomal fl-hexosaminidase and 
Table 5 
Hydrolysis of various fluorogenic glucosides by EMGlc-ase from human 
kidney 
Substrate Spec. act. (nmol/h per mg protein) 
MGlc 1.6 
EMGlc 39.6 
BMGIc 15.8 
OMGIc 5.9 
HMGlc 2.0 
The results obtained show that 6-acylamino-4-methyl- 
umbelliferyl-/3-o-glucosides are unattractive substrates for 
the detection of lysosomal and non-lysosomal glucocere- 
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Fig. 6. Subcellular distribution of/3-glucosidase activities in rat liver. The 
enzyme activities were measured as follows: lysosomal glucocerebrosi- 
dase ([]) as CBE-sensitive hydrolysis of MGlc in the presence of 0.6% 
(w/v) TCh and 0.1% (v/v)  Triton X- 100; non-lysosomal glucocerehrosi- 
dase (• )  as CBE-insensitive hydrolysis of MGIc without further addi- 
tions; EMGlc-ase (• )  as CBE-insensitive hydrolysis of EMGlc in the 
presence of 0.6% (w/v) TCh and 0.1% (v/v)  Triton X-100; hex- 
osaminidase (O)  as hydrolysis of MGlcNAc in the presence 0.1% (v/v) 
Triton X- 100. 
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Table 7 
Comparison of properties of different fl-glucosidases 
Parameter Lysosomal Non-lysosomal Cytosolic broad-specificity EMGlc-ase 
glucocerbrosidase glucocerebrosidase /3-glucosidase 
Hydrolysis of: 
glucosylceramide yes yes no no 
MGlc yes yes yes no 
EMGlc no no no yes 
Deficient in Gaucher disease yes no no no 
Inhibition by: 
CBE yes no no no 
D-(1,5)-gluconolatone weak [15] strong [9] moderate [15] no 
deoxynojirimycin strong moderate [9] unknown weak 
castanospermine strong moderate [9] strong [29] weak 
Effect of TCh activate inhibit inhibit activate 
Bound by Con A yes unknown no yes 
pH optimum 4.5 5.5 6.0 4.5 
Isoelectric point heterogeneous (3.5-7.0) unknown 4.6 5.0 
Subcellular localization lysosomal non-lysosomal cytosolic lysosomal 
brosidases as well as for cytosolic broad-specificity fl-glu- 
cosidase. The low reactivity of lysosomal glucocerebrosi- 
dase towards these substrates i  somewhat surprising, since 
it is known that their chromogenic analog, 2-hexa- 
decanoylamino-4-nitrophenyl-fl-D-glucoside, is a good 
substrate for this enzyme [26,27]. Moreover, 6-acylamino- 
4-methylumbelliferyl-/3-D-galactosides w th higher acyl- 
chain lengths are found to be good substrates for the 
lysosomal galactocerebrosidase [20,28]. 
The use of 6-acylamino-4-methylumbelliferyl-fl-D-glu- 
cosides led us to the identification of a hitherto unde- 
scribed /3-glucosidase isozyme. The enzyme is clearly 
distinct in properties from the known /3-glucosidases (see 
Table 7). It is a soluble lysosomal enzyme with a discrete 
pI of 5.0. It is not deficient in Gaucher disease, is not 
inhibited by CBE and by gluconolactone and is activated 
by sodium taurocholate. Its substrate specificity is remark- 
able, showing high affinity to 6-ethanoylamino-4-methyl- 
umbelliferyl-/3-D-glucoside but decreasing affinity to 6- 
acylamino-4-methylumbelliferyl-/3-D-glucosides with 
higher acyl chain length and low affinity to 4-methyl- 
umbelliferyl-/3-D-glucoside. It was impossible to demon- 
strate the glucocerebrosidase ctivity for the enzyme. The 
physiological substrate for the enzyme, that has been shown 
to be present in all tissues and cell types investigated, is 
therefore completely unknown at the moment. High affin- 
ity to Con A suggests that the enzyme is a glycoprotein. 
Purification of the enzyme to homogeneity and production 
of specific antibodies eem warranted to obtain a better 
insight into its precise composition and clues concerning 
its physiological function. 
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